Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141294

Published: 2020

Journal Articles

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-141264

Published: 2020

Journal Articles

Treating MRD Positivity in Multiple Myeloma: An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Long-Term Remissions in Patients with Low Disease Burden

Luca Biavati, MD, Carol Ann Huff, MD, Anna Ferguson, BSN, RN, Lakshmi Rudraraju, MS, Cristina Zucchinetti, Rachel Gittelman, Sarah Johnson, Catherine Sanders, Abbas Abbas Ali, MD, Kimberly Noonan, PhD MPH, Ivan M. Borrello, MD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-142620

Published: 2020

Journal Articles

An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Durable Remissions and Sustained Immunological Responses in Multiple Myeloma

Luca Biavati, MD, Anna Ferguson, BSN, RN, Carol Ann Huff, MD, Lakshmi Rudraraju, MS, Rachel Gittelman, Sarah Johnson, Catherine Sanders, Syed Abbas Ali, MD, Kimberly Noonan, PhD MPH, Ivan M. Borrello, MD

Blood (2019) 134 (Supplement_1): 1895.

https://doi.org/10.1182/blood-2019-128430

Published: 2019

Journal Articles

Superior Efficacy of CAR-T Cells Using Marrow-Infiltrating Lymphocytes (MILs TM ) As Compared to Peripheral Blood Lymphocytes (PBLs)

Eric R. Lutz, PhD, Srikanta Jana, PhD, Lakshmi Rudraraju, MS, Elizabeth DeOliveira, Jing Zhou, Sean Mackay, Ivan M. Borrello, MD, Kimberly Noonan, PhD MPH

Blood (2019) 134 (Supplement_1): 4437.

https://doi.org/10.1182/blood-2019-130629

Published: 2019

Journal Articles

Flowct: A Semi-Automated Workflow for Deconvolution of Immunophenotypic Data and Objective Reporting on Large Datasets

Blood (2019) 134 (Supplement_1): 4355.

https://doi.org/10.1182/blood-2019-122088

Published: 2019

Journal Articles

Marrow-Infiltrating Lymphocytes (MILs) Provide a Robust Platform for CAR-T Cell Therapy

Eric R. Lutz, PhD, Valentina Hoyos, MD, Lakshmi Rudraraju, MS, Elizabeth DeOliveira, Srikanta Jana, PhD, Ido Weiss, PhD, Ivan M. Borrello, MD, Kimberly Noonan, PhD MPH

Blood (2018) 132 (Supplement 1): 3337.

https://doi.org/10.1182/blood-2018-99-118580

Published: 2018

Journal Articles

FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant

Blood (2017) 130 (Supplement 1): 2593.

https://doi.org/10.1182/blood.V130.Suppl_1.2593.2593

Published: 2017

Journal Articles

Impaired Response to Influenza Vaccination in AML Patients Post-Chemotherapy Associated with a Highly Atypical B-Cell Profile

Meghali Goswami, Gabrielle T. Prince, MD, Angelique Biancotto, PhD, Susan Moir, PhD, Foo Cheung, PhD, Yuri Kotliarov, PhD, Kimberly Dunham, Jinguo Chen, MD, Rongye Shi, MD, Huizhi Zhou, Hana Golding, PhD, Jingrong Tang, MD PhD, John S. Tsang, PhD, Howard B. Dickler, MD, Kimberly Noonan, PhD MPH, B. Douglas Smith, MD, Ivan M. Borrello, MD, Christopher S. Hourigan, MD PhD

Blood (2015) 126 (23): 3427.

https://doi.org/10.1182/blood.V126.23.3427.3427

Published: 2015

Journal Articles

Allogeneic Myeloma GVAX with Lenalidomide Enhances Progression Free Survival through the Generation of Tumor Specific Immunity in Patients in Near Complete Remission

Ivan M. Borrello, MD, Kimberly Noonan, PhD MPH, Carol Ann Huff, Anna Ferguson, BSN, RN, Amy Sidorski, CRNP, Lakshmi Rudraraju, Raffaello Cimbro, MS, Luigi Marchionni, MD PhD

Blood (2015) 126 (23): 4238.

https://doi.org/10.1182/blood.V126.23.4238.4238

Published: 2015

Journal Articles

The Long PD-1 Receptor Binding Kinetics of Nivolumab May Increase Efficacy of Subsequent Therapy in Relapsed and Refractory Multiple Myeloma Patients

Samuel A. Funt, MD, David B. Page, MD, Deepika Cattry, BSc, MSc, Nikoletta Lendvai, MD PhD, Hani Hassoun, MD, Ola Landgren, MD PhD, Ivan M. Borrello, MD, Alexander M. Lesokhin, MD

Blood (2015) 126 (23): 3057.

https://doi.org/10.1182/blood.V126.23.3057.3057

Published: 2015

Journal Articles

Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) In Multiple Myeloma With Post-Transplantation Cyclophosphamide (PTCy)

Nilanjan Ghosh, MD, PhD, Xiaobu Ye, MD, MS, Javier Bolaños-Meade, MD, Ephraim J. Fuchs, Leo Luznik, Jennifer A. Kanakry, Robert A. Brodsky, MD, Mark Levis, MD, PhD, Lode J. Swinnen, Douglas Gladstone, MD, Yvette L. Kasamon, Richard F. Ambinder, Richard J. Jones, William Matsui, MD, Ivan M. Borrello, MD, Carol Ann Huff, M.D.

Blood (2013) 122 (21): 3407.

https://doi.org/10.1182/blood.V122.21.3407.3407

Published: 2013

Journal Articles

Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis

Robert J. Arceci, M.D., Ph.D., Carl E. Allen, MD, PhD, Ira Dunkel, M.D., Eric D. Jacobsen, MD, James Whitlock, Robert Vassallo, M.D., Ivan M. Borrello, MD, Allen Oliff, MD, Shannon R. Morris, MD, PhD, Beth Ann M Reedy, Alison Portnoy, Deborah A. Smith, PharmD, Bob Noble, Amy A. Murnane, Stephen A. Szabo, Carlos Rodriguez-Galindo, Mark L. Heaney, MD, PhD, Kenneth L. McClain, MD, PhD, Sarah Vaseilbuh, MD

Blood (2013) 122 (21): 2907.

https://doi.org/10.1182/blood.V122.21.2907.2907

Published: 2013

Journal Articles

Administration Of An Oral PDE5 Inhibitor, Tadalafil In Conjunction With a Lenalidomide Containing Regimen In Patients With Multiple Myeloma

Nilanjan Ghosh, MD, PhD, Lakshmi Rudraraju, MS, Xiaobu Ye, MD, MS, Kimberly Noonan, PhD, MPH, Carol Ann Huff, M.D., Ivan M. Borrello, MD

Blood (2013) 122 (21): 1959.

https://doi.org/10.1182/blood.V122.21.1959.1959

Published: 2013

Journal Articles

Addition Of Clarithromycin To Lenalidomide and Dexamethasone (BiRd) Is Effective In Multiple Myeloma After Progression On Lenalidomide and Dexamethasone

Nilanjan Ghosh, MD, PhD, Noah Tucker, Marianna Zahurak, M.S., Jocelyn L. Wozney, MD, Ivan M. Borrello, MD, Carol Ann Huff, M.D.

Blood (2013) 122 (21): 1960.

https://doi.org/10.1182/blood.V122.21.1960.1960

Published: 2013

Journal Articles

Dissecting The Potential Role Of Prevnar As An Anti-Myeloma Vaccine

Kimberly Noonan, PhD, MPH, Lakshmi Rudraraju, MS, Anna Ferguson, RN, Amy Sidorski, NP, Andrea Casildo, BS, Ervin Griffin, Susan Lee, BS, Nilanjan Ghosh, MD, PhD, William Matsui, MD, Carol Huff, M.D., Ivan M. Borrello, MD

Blood (2013) 122 (21): 1980.

https://doi.org/10.1182/blood.V122.21.1980.1980

Published: 2013

Journal Articles

A Novel Role of Histone Deacetylase 11 (HDAC11) in Regulation of Myeloid-Derived Suppressor Cell (MDSC) Expansion

Eva Sahakian, Ph.D, John Powers, B.S., Jennifer Rock-Klotz, B.S., Marsilio Adriani, Ph.D, Karrune V. Woan, Oscar Merino, Ajaypal S. Gill, Susan Deng, Fengdong Cheng, MD, Alejandro Villagra, Noreen Luetteke, Edward Seto, Eduardo M. Sotomayor, Ivan M. Borrello, MD, Javier Pinilla-Ibarz, MD, PhD

Blood (2011) 118 (21): 2439.

https://doi.org/10.1182/blood.V118.21.2439.2439

Published: 2011

Journal Articles

Enrichment of Allogeneic Tumor Antigen-Specific T Cells From Bone Marrow (BM) of Patients Treated with High-Dose Post-Transplant Cyclophoshamide (Cy) – A Novel Approach to Adoptive Immunotherapy

Kimberly Noonan, MPH, Leo Luznik, MD, Ivan M. Borrello, MD

Blood (2011) 118 (21): 647.

https://doi.org/10.1182/blood.V118.21.647.647

Published: 2011

Journal Articles

Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting

Kimberly Noonan, MPH, Carol A. Huff, MD, Janice M Davis Sproul, MAS, MT(ASCP), SBB, Mario Victor M Lemas, PhD, Lakshmi Rudraraju, MS, Leo Luznik, Jonathan Powell, MD, PhD, Javier Bolaños-Meade, Jeffrey Bitzan, MT, Susan Fiorino, MT(ASCP), William Matsui, MD, Richard J. Jones, MD, Ivan M. Borrello, MD

Blood (2011) 118 (21): 997.

https://doi.org/10.1182/blood.V118.21.997.997

Published: 2011

Journal Articles

Bortezomib and Thalidomide, a Steroid Free Regimen in Newly Diagnosed Patients with Multiple Myeloma.

Nilanjan Ghosh, Anna Ferguson, RN, Xiaobu Ye, Carol A. Huff, MD, Ivan M. Borrello, MD

Blood (2009) 114 (22): 2867.

https://doi.org/10.1182/blood.V114.22.2867.2867

Published: 2009

NARROW

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Treating MRD Positivity in Multiple Myeloma: An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Long-Term Remissions in Patients with Low Disease Burden

An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Durable Remissions and Sustained Immunological Responses in Multiple Myeloma

Superior Efficacy of CAR-T Cells Using Marrow-Infiltrating Lymphocytes (MILs TM ) As Compared to Peripheral Blood Lymphocytes (PBLs)

Flowct: A Semi-Automated Workflow for Deconvolution of Immunophenotypic Data and Objective Reporting on Large Datasets

Marrow-Infiltrating Lymphocytes (MILs) Provide a Robust Platform for CAR-T Cell Therapy

FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant

Impaired Response to Influenza Vaccination in AML Patients Post-Chemotherapy Associated with a Highly Atypical B-Cell Profile

Allogeneic Myeloma GVAX with Lenalidomide Enhances Progression Free Survival through the Generation of Tumor Specific Immunity in Patients in Near Complete Remission

The Long PD-1 Receptor Binding Kinetics of Nivolumab May Increase Efficacy of Subsequent Therapy in Relapsed and Refractory Multiple Myeloma Patients

Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) In Multiple Myeloma With Post-Transplantation Cyclophosphamide (PTCy)

Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis

Administration Of An Oral PDE5 Inhibitor, Tadalafil In Conjunction With a Lenalidomide Containing Regimen In Patients With Multiple Myeloma

Addition Of Clarithromycin To Lenalidomide and Dexamethasone (BiRd) Is Effective In Multiple Myeloma After Progression On Lenalidomide and Dexamethasone

Dissecting The Potential Role Of Prevnar As An Anti-Myeloma Vaccine

A Novel Role of Histone Deacetylase 11 (HDAC11) in Regulation of Myeloid-Derived Suppressor Cell (MDSC) Expansion

Enrichment of Allogeneic Tumor Antigen-Specific T Cells From Bone Marrow (BM) of Patients Treated with High-Dose Post-Transplant Cyclophoshamide (Cy) – A Novel Approach to Adoptive Immunotherapy

Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting

Bortezomib and Thalidomide, a Steroid Free Regimen in Newly Diagnosed Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only